A Study to Assess Adverse Events and Disease Activity with Cedirogant (ABBV-157) in Adult Participants withModerate to Severe Psoriasis
Phase 2
Suspended
- Conditions
- Psoriasis
- Registration Number
- JPRN-jRCT2061210069
- Lead Sponsor
- Yamazaki Hayato
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Suspended
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Participants with stable moderate to severe plaque psoriasis of at least 6 months duration and who are candidates for systemic therapy or phototherapy.
Exclusion Criteria
- Primary non-responders to previous anti-IL-17 (e.g., secukinumab, ixekizumab, brodalumab), anti-IL-23 (e.g., guselkumab, tildrakizumab, risankizumab), or anti-IL-12/23 (e.g., ustekinumab) treatment for chronic plaque psoriasis.
- Diagnosis of erythrodermic psoriasis, generalized or localized pustular psoriasis, medication-induced or
medication exacerbated psoriasis, or new onset guttate psoriasis or any other skin disease which may interfere with assessment of chronic plaque psoriasis.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method